Mertiva AB

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

University of Florida Research Foundation and Diamyd Medical settle lawsuit

Thu, Nov 17, 2011 08:30 CET

University of Florida Research Foundation, Incorporated (“UFRF”), and Diamyd Medical AB today jointly announced that they have settled the breach of contract litigation that UFRF filed in the United States Federal District Court in Florida against Diamyd Medical in January 2011.The dispute related to an exclusive license agreement between UFRF and Diamyd Medical, and to a sublicense of the rights under the exclusive license agreement between Diamyd Medical and Ortho-McNeil-Janssen Pharmaceuticals, Inc., which sublicense involved rights to the GAD65-based drug candidate Diamyd®. UFRF and

Diamyd receives compensation from Apoteket AB

Wed, Oct 14, 2009 12:11 CET

Diamyd Medical announces today that the company has executed a settlement agreement with Apoteket AB regarding a clinical study in LADA patients, which was invalidated in 2007. The cause of the invalidation was contradictory data, which gave reason to suspect a mix-up of active drug and placebo.Diamyd contracted Apoteket AB in 2004 for handling of blinding, randomization and labeling of the study drug for a clinical study with 160 LADA patients. As the study was unblinded and reported during summer 2007, the data was found to be inconclusive. An inspection at the pharmacy, that had handled

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

University of Florida Research Foundation and Diamyd Medical settle lawsuit

Diamyd receives compensation from Apoteket AB

Media